These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8292720)

  • 1. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.
    Valentin S; Nordfang O; Bregengård C; Wildgoose P
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue factor pathway inhibitor; its structure, function and clinical significance.
    Kato H
    Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits.
    Bregengaard C; Nordfang O; Ostergaard P; Petersen JG; Meyn G; Diness V; Svendsen O; Hedner U
    Thromb Haemost; 1993 Sep; 70(3):454-7. PubMed ID: 8259548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein.
    Horie S; Hiraishi S; Hamuro T; Kamikubo Y; Matsuda J
    Thromb Haemost; 2002 Jan; 87(1):80-5. PubMed ID: 11848461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of lipoprotein lipase activity by tissue factor pathway inhibitor.
    Mukherjee M; Kakkar VV
    Thromb Haemost; 1999 Dec; 82(6):1648-51. PubMed ID: 10613650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
    Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of plasma tissue factor pathway inhibitor.
    Broze GJ; Lange GW; Duffin KL; MacPhail L
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):551-9. PubMed ID: 7841311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids.
    Valentin S; Schousboe I
    Thromb Haemost; 1996 May; 75(5):796-800. PubMed ID: 8725726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of native VLDL on tissue factor pathway inhibitor in endothelial cells and interactions between TFPI and lipoprotein lipase.
    Brodin E; Iversen N; Hansen JB
    J Lab Clin Med; 2006 Apr; 147(4):167-73. PubMed ID: 16581344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor: proposed heparin recognition region.
    Harenberg J; Malsch R; Heene DL
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S50-6. PubMed ID: 7647222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
    Cunningham AC; Hasty KA; Enghild JJ; Mast AE
    Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of the carboxy-terminal domain of lipoprotein lipase to interaction with heparin and lipoproteins.
    Lookene A; Nielsen MS; Gliemann J; Olivecrona G
    Biochem Biophys Res Commun; 2000 Apr; 271(1):15-21. PubMed ID: 10777674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
    Piro O; Broze GJ
    Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.
    Alban S
    Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
    Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T
    Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of thrombin generation by TFPI in plasma without and with heparin.
    Brodin E; Appelbom H; Osterud B; Hilden I; Petersen LC; Hansen JB
    Transl Res; 2009 Mar; 153(3):124-31. PubMed ID: 19218095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.
    Warshawsky I; Bu G; Mast A; Saffitz JE; Broze GJ; Schwartz AL
    J Clin Invest; 1995 Apr; 95(4):1773-81. PubMed ID: 7706485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present status of tissue factor pathway inhibitor.
    Lindahl AK; Sandset PM; Abildgaard U
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
    Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
    J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.